Summary
Attempts were made to identify factors related to the response of patients treated with intravenous methotrexate, vinblastine, Adriamycin, and cisplatin (M-VAC). The subjects consisted of 54 patients with advanced urothelial cancer whose histological type was transitional-cell carcinoma. The effects of various factors on the response were studied using univariate analysis and a multiple logistic regression model. The following factors were included in the anlayses: (1) age, (2) sex, (3) performance status (PS), (4) primary site, (5) histological grade, (6) T category, (7) N category, (8) M category, (9) tumor status, and (10) dose of drugs. In all, 9 patients achieved a complete response and 23 showed a partial response, for an overall response rate of 59% (95% confidence limits, 46%–72%). Univariate analysis revealed that the PS, M category, and dose of drugs were related to the response, and there was a significant correlation among these three factors. In the multiple logistic regression model, the absolute value oft was high for the M category. The presence of distant metastases is an important factor in predicting poor efficacy for the present regimen. The management of metastatic disease will be the subject of further study in the treatment of advanced urothelial cancer.
Similar content being viewed by others
References
Freiha F, Vries C de, Torti F (1988) Neoadjuvant and adjuvant chemotherapy of transitional cell carcinoma of the urothelium with cisplatin, methotrexate and vinblastine. World J Urol 6: 153
Hortobagyi GN, Smith TL, Legha SS, Swenerton KD, Gehan EA, Yap H-Y, Buzdar AU, Blumenschein GR (1983) Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1: 776
Igawa M, Ohkuchi T, Ueki T, Ueda M, Okada K, Usui T (1990) Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. J Urol 144: 662
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457
Lee E (1980) Identification of risk factor related dichotomous data. In: (eds) Statistical methods for survival data analysis. Lifetime Learning, California, p 338
Schwartz S, Yagoda A, Natale RB, Watson RC, Whitmore WF, Lesser M (1983) Phase II trial of sequentially administered cisplatin, cyclophosphamide and doxorubicin for urothelial tract tumors. J Urol 130: 681
Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, Geller N, Hollander PS, Herr HW, Sogani PC, Morse MJ, Whitmore WF (1985) Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133: 403
Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, Morse MJ, Sogani PC, Vaughan ED Jr, Bander N, Weiselberg LR, Geller N, Hollander PS, Lipperman R, Fair WR, Whitmore WF Jr (1988) M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 139: 461
Troner MB, Hemstreet GP III (1981) Cyclophosphamide, doxorubicin and cisplatin (CAP) in the treatment of urothelial malignancy: a pilot study of the Southeastern Cancer Study Group. Cancer Treat Rep 65: 29
World Health Organization (1979) Handbook for reporting results of cancer treatment WHO, Geneva
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Igawa, M., Ohkuchi, T., Ueda, M. et al. Factors affecting the outcome of patients with advanced urothelial cancer following chemotherapy with methotrexate, vinblastine, Adriamycin, and cisplatin. Cancer Chemother. Pharmacol. 30 (Suppl 1), S77–S80 (1992). https://doi.org/10.1007/BF00686948
Issue Date:
DOI: https://doi.org/10.1007/BF00686948